Mirati Therapeutics (Mirati Therapeutics) Debt-to-Equity : 0.05 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Debt-to-Equity?

Mirati Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $8.02 Mil. Mirati Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $42.20 Mil. Mirati Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $946.47 Mil. Mirati Therapeutics's debt to equity for the quarter that ended in Sep. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mirati Therapeutics's Debt-to-Equity or its related term are showing as below:

MRTX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.04 Max: 0.07
Current: 0.05

During the past 13 years, the highest Debt-to-Equity Ratio of Mirati Therapeutics was 0.07. The lowest was 0.03. And the median was 0.04.

MRTX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs MRTX: 0.05

Mirati Therapeutics Debt-to-Equity Historical Data

The historical data trend for Mirati Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Debt-to-Equity Chart

Mirati Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.05

Mirati Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.05	0.06	0.07	0.05

Competitive Comparison of Mirati Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Mirati Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirati Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's Debt-to-Equity falls into.

Mirati Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mirati Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.844	+	43.661)	/	996.516
	=	0.05

Mirati Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.02	+	42.203)	/	946.465
	=	0.05

Mirati Therapeutics (NAS:MRTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mirati Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirati Therapeutics (Mirati Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

26M:Germany

Address

3545 Cray Court, San Diego, CA, USA, 92121

Website

https://www.mirati.com

Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.

Executives

Jamie Christensen	officer: Sr. Vice President, Chief Scie	C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey	officer: EVP, Chief Commercial Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey	officer: Interim CFO	3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake	other: See remarks	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty	officer: Chief Legal Officer	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer	officer: CFO	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington	director	9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121